Edition:
India

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

11.07USD
2:29am IST
Change (% chg)

$0.14 (+1.28%)
Prev Close
$10.93
Open
$10.96
Day's High
$11.36
Day's Low
$10.96
Volume
43,836
Avg. Vol
106,833
52-wk High
$25.95
52-wk Low
$5.42

Chart for

About

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which... (more)

Overall

Beta: --
Market Cap(Mil.): $128.07
Shares Outstanding(Mil.): 13.26
Dividend: --
Yield (%): --

Financials

BRIEF-Zynerba Pharmaceuticals Inc ‍Plans To Initiate Phase 2 Development Of ZYN001 In Tourette Syndrome By Year End ​

* ZYNERBA PHARMACEUTICALS PROVIDES 2018 CLINICAL AND CORPORATE UPDATE

04 Jan 2018

BRIEF-Zynerba Pharmaceuticals reports Q3 loss per share of $0.63

* Zynerba Pharmaceuticals reports third quarter 2017 financial results and operational highlights

14 Nov 2017

Zynerba's stock on a high as cannabis-based drug succeeds in trial

Zynerba Pharmaceuticals Inc said on Thursday its cannabis-derived gel to treat genetic disorder Fragile X syndrome succeeded in significantly reducing symptoms such as anxiety in a mid-stage study.

28 Sep 2017

BRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study

* Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study in children with Fragile X syndrome

28 Sep 2017

Zynerba's cannabis-based gel succeeds in mid-stage study

Sept 28 Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel succeeded in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities.

28 Sep 2017

Earnings vs. Estimates